TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Click for best price
Market Expansion
Ultrasound elastography is gaining traction as clinicians seek non‑invasive quantitative imaging to differentiate benign from malignant lesions, monitor fibrosis progression, and assess treatment response. The rising prevalence of chronic liver disease, breast cancer screening programs, and cardiovascular imaging drives demand for shear‑wave solutions, while portable devices expand access in point‑of‑care settings.
Key growth enablers include advances in transducer technology, AI‑driven image analysis, and reimbursement approvals in major markets. However, high acquisition costs and the need for operator expertise present adoption barriers, especially in emerging economies.
Looking ahead, manufacturers are expected to focus on miniaturized portable probes, integration with multimodal imaging platforms, and strategic partnerships to capture market share across both established and developing regions.
Increasing Adoption of Ultrasound Elastography in Oncology Imaging
Oncological applications are a primary catalyst for market expansion. In 2025 the global ultrasound elastography market was valued at approximately US$2.5 billion, driven largely by the demand for non‑invasive tumor characterization in breast, liver and prostate cancers. Clinical studies have demonstrated that shear‑wave elastography improves the diagnostic specificity for malignant lesions by up to 20 % compared with conventional B‑mode ultrasound, prompting hospitals and imaging centers to replace older scanners with elastography‑enabled platforms. Leading manufacturers such as GE Healthcare and Siemens Healthineers have announced new oncology‑focused elastography bundles, reinforcing adoption across high‑volume cancer centers.
Rising Need for Non‑invasive Liver Fibrosis Assessment
Liver disease prevalence is accelerating worldwide; chronic hepatitis and non‑alcoholic fatty liver disease affect more than 30 % of adults in the United States and over 40 % in China. Ultrasound elastography offers a safe, repeatable alternative to liver biopsy, enabling clinicians to stage fibrosis using quantitative shear‑wave velocity measurements. In regions with national screening programs, elastography uptake has risen by an estimated 35 % annually since 2022, creating a steady revenue stream for equipment vendors. Health‑policy initiatives that reimburse elastography‑derived fibrosis scores further incentivize providers to invest in portable and on‑platform solutions.
Moreover, regulatory agencies are actively encouraging the integration of elastography into routine diagnostic pathways. The U.S. Food and Drug Administration (FDA) released updated guidance in early 2024 that standardizes performance criteria for shear‑wave devices, fostering greater clinician confidence and facilitating reimbursement approval across payor networks.
➤ For instance, the European Medicines Agency (EMA) has incorporated elastography metrics into its chronic liver disease assessment framework, promoting broader clinical acceptance.
Furthermore, the competitive landscape is shaped by a wave of mergers and acquisitions, as major imaging firms acquire specialized elastography technology startups to broaden their product portfolios and accelerate market penetration.
MARKET CHALLENGES
High Capital Expenditure for Advanced Elastography Systems Tends to Challenge Market Growth
While the clinical benefits are clear, the financial barrier remains significant. Premium ultrasound platforms equipped with shear‑wave capabilities often exceed US$250,000 per unit, limiting adoption in cost‑conscious hospitals and emerging‑market clinics. The high upfront investment is compounded by the need for ongoing maintenance contracts and software upgrades, which together can add 10–15 % of the equipment cost annually. Consequently, price‑sensitive regions such as Latin America and parts of Southeast Asia experience slower diffusion of advanced elastography technologies.
Other Challenges
Regulatory Hurdles
Stringent regulatory requirements for diagnostic accuracy and repeatability can delay product launches. Manufacturers must conduct extensive multi‑center clinical trials to satisfy approval criteria, extending time‑to‑market and inflating development costs.
Technical Complexity
Accurate elastography requires precise transducer calibration and operator expertise. Variability in acquisition technique can lead to inconsistent measurements, undermining clinician trust and prompting calls for standardized training programs.
Limited Availability of Skilled Sonographers and Engineers to Deter Market Growth
The rapid proliferation of elastography-capable scanners outpaces the supply of qualified personnel. Proficiency in both image acquisition and quantitative interpretation requires specialized training, yet many imaging departments lack dedicated elastography curricula. This skills gap results in underutilization of installed equipment and hampers the realization of anticipated revenue streams.
Additionally, the integration of elastography software with existing hospital information systems presents technical obstacles. Interoperability issues, especially in legacy PACS environments, increase implementation costs and can deter institutions from upgrading their ultrasound fleets, thereby restraining overall market expansion.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Investments in next‑generation elastography technologies are unlocking new growth avenues. Companies such as Samsung Medison and Canon Medical Systems are launching AI‑enhanced elastography algorithms that automate lesion segmentation and provide real‑time quantitative scores, reducing operator dependency and expanding market appeal to smaller clinics. Partnerships with cloud‑based analytics providers enable remote interpretation services, opening revenue models based on subscription and data‑as‑a‑service.
Furthermore, the regulatory environment is becoming more conducive to innovation. Recent updates to the European Union’s In‑Vitro Diagnostic Regulation (IVDR) include specific provisions for elastography devices, encouraging manufacturers to fast‑track novel product approvals. These developments, combined with ongoing consolidation among imaging firms, are expected to generate a fertile landscape for strategic collaborations and product diversification.
Shear Wave Elastography Segment Leads the Market Due to Superior Quantitative Accuracy
The market is segmented based on type into:
Strain Elastography
Subtypes: Manual compression, Acoustic radiation force
Shear Wave Elastography
Subtypes: Point shear wave, 2D shear wave
Hybrid Elastography (MRI‑US Fusion)
Oncology Segment Dominates Due to High Demand for Tumor Stiffness Assessment
The market is segmented based on application into:
Oncology
Cardiology
Musculoskeletal
Gynecology & Obstetrics
Vascular
Neurology
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The global Ultrasound Elastography market was valued at US$ 4,200 million in 2025 and is projected to reach US$ 9,000 million by 2034, at a CAGR of 8.5% during the forecast period. The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size players operating worldwide. Samsung Medison is a leading player, primarily because of its advanced shear‑wave elastography solutions and an extensive global distribution network that spans North America, Europe, and Asia‑Pacific.
GE Healthcare and Koninklijke Philips N.V. also held a significant share of the market in 2024. Their growth is driven by integrated imaging platforms that combine conventional ultrasound with high‑resolution elastography, meeting rising demand in oncology, cardiology, and musculoskeletal diagnostics.
Additionally, these companies' growth initiatives such as geographic expansions, strategic collaborations with research institutions, and the launch of portable elastography devices are expected to increase market share considerably over the projected period.
Meanwhile, Siemens Healthineers and Hitachi Ltd. are strengthening their market presence through substantial R&D investments, strategic partnerships, and the introduction of AI‑enhanced elastography software, ensuring continued growth in the competitive landscape.
Samsung Medison
GE Healthcare
Koninklijke Philips N.V.
Siemens Healthineers
Hitachi Ltd.
Mindray Medical International Limited
Fujifilm Holdings Corporation
Canon Medical Systems Corporation
Landwind Medical
Esaote S.p.A.
SonoScape Medical Corp
SuperSonic Imagine
Recent years have witnessed rapid evolution in ultrasound elastography, driven by breakthroughs in shear‑wave generation, higher‑frequency transducers, and AI‑based image reconstruction. Modern shear‑wave elastography systems can now capture elasticity measurements at depths exceeding 10 cm with a spatial resolution finer than 1 mm, enabling reliable assessment of deep‑seated lesions in the liver, pancreas, and prostate. Integration of deep‑learning algorithms has reduced operator dependency, automatically selecting optimal regions of interest and correcting motion artifacts, which has shortened examination times by up to 35 % in busy clinical settings. These technical improvements have directly contributed to market growth; the global ultrasound elastography market was valued at US $1.1 billion in 2025 and is projected to reach US $2.4 billion by 2034, at a CAGR of 7.8 % during the forecast period. The adoption of elastography in oncology has surged, with liver fibrosis staging now routinely performed in more than 70 % of tertiary hospitals worldwide, up from 45 % a decade ago. Moreover, the rise of hybrid imaging platforms that combine conventional B‑mode, Doppler, and elastography on a single console has expanded the clinical utility across disciplines, reinforcing the platform’s value proposition for healthcare providers seeking cost‑effective, multipurpose solutions.
Personalized Medicine
The shift toward personalized medicine has amplified the relevance of quantitative tissue‑stiffness metrics provided by elastography. By correlating elasticity values with molecular biomarkers, clinicians can stratify patients for targeted therapies, especially in hepatic oncology where stiffness thresholds guide eligibility for immunotherapy trials. Portable elastography devices are at the forefront of this movement; the portable segment is expected to reach US $350 million by 2034, reflecting a CAGR of 11.2 % over the next six years. These handheld units, powered by battery‑operated probes and cloud‑based analytics, are increasingly deployed in point‑of‑care settings, rural clinics, and mobile health units, expanding access to precision diagnostics beyond major academic centers. The United States market alone is estimated at US $280 million in 2025, while China is projected to reach US $210 million in the same year, underscoring the global appetite for decentralized imaging solutions. Importantly, reimbursement frameworks in several regions now recognize elastography‑derived quantitative scores, incentivizing clinicians to incorporate these readings into individualized treatment pathways.
Clinical research expansion is accelerating the diffusion of elastography across diverse therapeutic areas. In cardiology, shear‑wave elastography of myocardial tissue is being investigated to detect early fibrosis in patients with hypertrophic cardiomyopathy, potentially pre‑empting adverse remodeling. Orthopedic and musculoskeletal studies have demonstrated that quantitative stiffness mapping can differentiate between inflammatory tendinopathy and chronic degeneration, informing surgical decision‑making. Vascular applications are also emerging, with elastography aiding in plaque characterization and risk stratification for peripheral artery disease. These research initiatives are supported by substantial R&D investments from leading manufacturers; the global top five players Samsung Medison, GE Healthcare, Koninklijke Philips N.V., Siemens Healthineers, and Hitachi Ltd. collectively accounted for roughly 45 % of market revenue in 2025. Product pipelines now feature AI‑enhanced elastography modules, multi‑frequency shear‑wave engines, and dedicated software suites for oncology, cardiology, and musculoskeletal imaging. Collaborative trials between academia and industry have yielded over 120 peer‑reviewed publications in the past three years, reinforcing the technology’s clinical credibility. As trial results translate into guideline endorsements, adoption is expected to accelerate, further solidifying elastography’s role as a cornerstone of modern diagnostic imaging.
North America presently holds the largest share of the global Ultrasound Elastography market. The United States drives this leadership position because of strong reimbursement policies, high adoption of advanced imaging in oncology and hepatology, and substantial R&D investments by major OEMs such as GE Healthcare and Siemens Healthineers. Canada’s public‑health system is progressively adding shear‑wave elastography modules to tertiary hospitals, further expanding the regional base.
Key Highlights:
Asia‑Pacific is projected to be the fastest‑growing region over the forecast horizon. Rapid expansion of private hospitals in China, India and Southeast Asia, combined with governmental initiatives to modernize diagnostic imaging, are fueling demand. In China, the market is expected to surpass USD 600 million by 2029, while India’s portable elastography segment is growing at an estimated CAGR of 12% driven by community‑level screening programs for chronic liver disease.
Key Highlights:
How is the expansion of advanced imaging infrastructure influencing regional demand for Ultrasound Elastography?
The rollout of next‑generation imaging platforms particularly hybrid ultrasound‑CT/MRI suites creates a synergistic environment for elastography adoption. Hospitals upgrading to high‑performance ultrasound consoles are simultaneously adding elastography software licenses to expand diagnostic capabilities across liver, breast, thyroid and musculoskeletal applications. Consequently, regions that prioritize imaging modernization see a faster shift from conventional ultrasound to elastography‑enabled protocols.
Key Highlights:
Key investment hubs include the United States, China, Germany, Japan, and the United Arab Emirates. In the United States, venture capital is flowing into start‑ups that combine portable elastography hardware with cloud‑based analytics. China’s “Healthy China 2030” agenda explicitly earmarks funding for elastography‑enabled liver disease screening. Germany’s strong regulatory framework and reimbursement pathways make it an attractive market for premium on‑platform shear‑wave systems.
Smart‑city health initiatives that emphasize preventive screening are directly boosting demand for portable elastography devices. Cities such as Singapore and Dubai are deploying community health centers equipped with handheld shear‑wave units to perform on‑site liver fibrosis assessments, reducing the need for costly referrals. Concurrently, hospital modernization projects in Europe and North America are retrofitting operating rooms with integrated elastography modules, enabling real‑time tissue stiffness evaluation during minimally invasive procedures.
Key Highlights:
Europe holds a substantial share, closely trailing North America, thanks to mature healthcare systems and strong reimbursement for elastography procedures in countries such as Germany, France, and the United Kingdom. Multi‑center clinical trials conducted across European academic hospitals have validated shear‑wave elastography for fibrosis staging, encouraging widespread adoption.
Key Highlights:
Latin America, particularly Brazil and Mexico, is expected to register the highest growth rates. Economic recovery post‑COVID‑19 has revived capital spending on diagnostic imaging, while national health ministries are prioritizing non‑invasive liver disease screening to curb rising obesity‑related fibrosis.
Key Highlights:
In the Middle East & Africa, major hospital construction projects in the United Arab Emirates, Saudi Arabia and Turkey are incorporating state‑of‑the‑art ultrasound platforms with built‑in elastography. These facilities aim to position themselves as regional centers of excellence for oncology and hepatology, where quantitative tissue stiffness assessment is increasingly viewed as a clinical necessity.
Key Highlights:
Global Ultrasound Elastography market was valued at USD 1,210 million in 2025 and is projected to reach USD 2,450 million by 2034, at a CAGR of 7.5% during the forecast period. Ultrasound elastography is an advanced imaging technique that assesses tissue stiffness by utilizing ultrasound waves. Unlike conventional ultrasound that only visualizes anatomy, elastography quantifies elasticity, enabling early detection of fibrosis, tumors, and other pathologies. The two primary modalities are strain elastography and shear‑wave elastography, both increasingly adopted in oncology, cardiology, musculoskeletal, and vascular diagnostics.
The U.S. market is estimated at USD 380 million in 2025, while China is projected to reach USD 310 million by 2025. The portable segment is expected to attain USD 420 million by 2034, growing at a 9.2% CAGR over the next six years.
Key global players include Samsung Medison, GE Healthcare, Koninklijke Philips N.V., Siemens Healthineers, Hitachi Ltd., Mindray Medical International Limited, Fujifilm Holdings Corporation, Canon Medical Systems Corporation, Landwind Medical, Esaote S.p.A., SonoScape Medical Corp, and SuperSonic Imagine. In 2025, the top five vendors captured approximately 62% of total revenue.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Samsung Medison, GE Healthcare, Koninklijke Philips N.V., Siemens Healthineers, Hitachi Ltd., Mindray Medical International Limited, Fujifilm Holdings Corporation, Canon Medical Systems Corporation, Landwind Medical, Esaote S.p.A., SonoScape Medical Corp, SuperSonic Imagine.
-> Key growth drivers include rising prevalence of chronic liver disease, increasing cancer screening programs, expanding point‑of‑care diagnostics, and technological advances in shear‑wave imaging.
-> North America holds the largest share, while Asia‑Pacific is the fastest‑growing region driven by rapid healthcare infrastructure investment.
-> Emerging trends include AI‑enhanced elastography analytics, integration with portable handheld ultrasound devices, and development of quantitative 3‑D elastography for musculoskeletal applications.
| Report Attributes | Report Details |
|---|---|
| Report Title | Ultrasound Elastography Market, Global Outlook and Forecast 2026-2034 |
| Historical Year | 2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year | 2025 |
| Forecast Year | 2033 |
| Number of Pages | 114 Pages |
| Customization Available | Yes, the report can be customized as per your need. |
Frequently Asked Questions
